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In many phase II trials in solid tumours, patients are assessed using endpoints
based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale.
Often, analyses are based on the response rate. This is the proportion of patients
who have an observed tumour shrinkage above a predefined level and no new
tumour lesions. The augmented binary method has been proposed to improve
the precision of the estimator of the response rate. The method involves mod-
elling the tumour shrinkage to avoid dichotomising it. However, in many trials
the best observed response is used as the primary outcome. In such trials,
patients are followed until progression, and their best observed RECIST out-
come is used as the primary endpoint. In this paper, we propose a method that
extends the augmented binary method so that it can be used when the outcome
is best observed response. We show through simulated data and data from a real
phase II cancer trial that this method improves power in both single-arm and
randomised trials. The average gain in power compared to the traditional anal-
ysis is equivalent to approximately a 35% increase in sample size. A modified
version of the method is proposed to reduce the computational effort required.
We show this modified method maintains much of the efficiency advantages.
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1 INTRODUCTION
A new cancer treatment is tested for potential benefit in phase II trials that use a relatively small number of patients
followed over a short period of time. The results of the phase II trial determines whether to test the treatment in a larger,
more time-consuming, and more costly phase III trial. Because of the high cost of, and high failure rate in, phase III
oncology trials,1 it is important to improve the analysis of phase II trials to ensure the decision is more accurate.
Phase II oncology trials use a variety of endpoints to evaluate the efficacy of a treatment.2,3 The most commonly used
endpoints in solid tumours are based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale.4 The RECIST
defines tumour size as the sum of longest diameters of target lesions and categorises patients into complete response
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(CR), partial response (PR), stable disease (SD), and progressive disease (PD). The CR and PR represent no new tumour
lesions and a 100% shrinkage and greater than 30% shrinkage, respectively; PD represents a 20% increase in tumour size
from the minimum size observed up to that point or new lesions appearing. Often patients are followed until they are
categorised as PD or a preplanned time, and patients with CR or PR are labelled responders. The endpoints for evaluating
a treatment include response rate and time to an event (progression/death). The response rate is defined as either (1)
proportion of patients who are responders at a certain time after baseline (fixed response) or (2) the proportion of patients
whose best observed response (BOR) before progression is CR or PR. A response endpoint classing CR and PR as success
is called objective response rate (ORR), which is often used in practice. Disease control rate additionally includes SD as
success. In some cases where response rate may not be the optimal method, a time to event endpoint “progression-free
survival” is considered, which is the time until PD or death. Response-based endpoints are an indicator of the relative
anti-tumour activity of the treatments and are not always highly predictive of overall survival. Improving the efficiency
of trials using response-based endpoints would help increase the success rate of phase III trials in tumour types where
response is predictive of overall survival.
Categorizing patients into responders and nonresponders is widespread and clinically appealing. However, it can
have substantial statistical disadvantages. Its major limitation is that it dichotomises the continuous tumour variable,
thus discarding information. This loses substantial efficiency.5 Some researchers have addressed the problem and
proposed methods to make use of the continuous change in tumour response to improve statistical efficiency. This
is done in different ways. Karrison et al6 propose directly using the change in tumour size as an endpoint. Wason
and Seaman7 use models for the tumour size and new lesion data which can be used to infer the fixed response rate
with higher precision. They find the Karrison's method was more powerful when the probability of new lesions was
different between arms but less powerful when the mean tumour size change was different. Jaki et al8 propose a
method that links tumour size change with mortality using historical datasets. Authors have demonstrated that using
continuous scales can increase the power (or reduce the required sample for a target power) compared to analysing the
binary composite outcome.
Focusing on response-based endpoints, the method of Wason and Seaman7 retains the clinically meaningful endpoint
but takes into account the continuous information on tumour size. This method is limited by only allowing 2 follow-up
visits and only considering response rate at a fixed time (ie, it cannot be used tomake inferences onBOR). In trials inwhich
patients are assessed twice (interim and final), theirmethod is sufficient. However, in trials where patients are followed up
until a preplanned time, a method incorporating information on all measurement data is preferred for efficiency reasons.
In this paper, we consider ORR and present an extended method that can be used for any number of follow-up times for
fixed response or BOR.We propose a modified version that uses a highly efficient technique for multivariate integration,9
which substantially reduces the computation time taken. We assess the properties of the proposed methods by using
simulated data and data from a real phase II cancer trial (HORIZON II).
This paper is divided into 4 sections. Section 2 gives a brief overview of the augmented binarymethod (Augbin).7 It then
describes the proposed extensions of the method. Section 3 evaluates the performance of the proposed methods using
simulations and real data. Section 4 summarizes the results and presents limitations and future work.
2 METHODS
2.1 Background
We use the phrase “tumour size” as shorthand for the sum of the longest diameter of target tumour lesions. We assume
patients tumour sizes are recorded until progression occurs or until a preplanned number of visits. We note there are 2
ways in which a progression can occur: an increase in tumour size by more than 20% (a tumour-growth progression) or
new lesions appearing (a new-lesion progression). Two response-based endpoints can be used in the analysis, one being
fixed time and the other being BOR. Analysis at a fixed time t uses the proportion of responders at time t (those who have a
tumour size shrinkage at time t above a predefined threshold and no progression up to that point). Best observed response
defines patients as a responder or not according to their BOR before progression. The latest RECIST guidelines4 give BOR
2 definitions according to whether confirmation is required or not. Confirmation means that an apparent response must
be backed up by continued response at the next time point to be counted as genuine. This is especially recommended for
single-arm trials. When confirmation is not required (randomised trials comparing 2 arms), BOR is defined as the best
response across all time points up to progression. When confirmation is required, BOR is defined as a response if the
patient is a responder at 2 consecutive time points before progression.
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2.2 Notation
Tumour sizes for each patient are measured at several discrete times (T denoting the maximum time). The tumour size
at time t for patient i is denoted by zit where t = 0 represents the baseline measurement. We denote G and X as the
time at which a tumour-growth progression and new-lesion progression occurs, respectively. Once a patient progresses
they are no longer followed up. The observed data is therefore (Fi, zi) where Fi = min(Xi,Gi,T). We define yit as the log
tumour size ratio for patient i at time t, yit = log(zit∕zi0), and ct as the prespecified dichotomisation threshold for response
(on the log tumour ratio scale). Further,Dit defines new-lesion progression indicators: {Dit = 1 if patient ihas a progression
due to new lesions occurring between time (t − 1) and t, t = 1, … ,T }. For simplicity, we define composite indicators
S for fixed time and BOR for best observed response using tumour progression relative to the baseline rather than nadir
(the lowest rumour size observed so far). Note that we show how to use the true definition in the Supporting Information.
In addition, we assume that response at a fixed timewouldmean just the response status at the specified time is of interest.
The response indicator for patient i using fixed time is defined as
Sit =
{
1, if Dij = 0 for all j = 1, … , t, yit < ct and no tumour progression before t,
0, otherwise.
For BOR, when confirmation is not required, the event is equivalent to having at least 1 record classified CR/PR before
progression or time T, the response indicator BORi is defined as
BORi =
{
1, if there exists a t such that yit < log(0.7), t ⩽ min(Fi,Xi − 1) and log(0.7) < yi1, … , yi(t−1) < log(1.2),
0, otherwise.
We consider the case where confirmation is required later. We lay out more fully how to incorporate the actual
definition of progression with change from nadir in the Supporting Information. This includes use of an indicator func-
tion for the extended augmented binary method (eAugbin) and a more exact method for the modified augmented binary
method (mAug).
2.3 Estimating response probability using the Augbin with 2 follow-up times
The augmented binary method, henceforth referred to as Augbin, was proposed by Wason and Seaman.7 We briefly
describe this method here, but more details are found in Wason and Seaman.7
The Augbin method makes assumptions that the log tumour size ratios follow a multivariate normal distribution, and
the probability of new-lesion progression depends only on the observed tumour size at the previous visit. The log tumour
size ratios are modelled by
(Yi1,Yi2)′|zi0 ∼ N((𝜇i1, 𝜇i2)′,Σ),
where 𝜇i1 = 𝛽1 + 𝜔zi0, 𝜇i2 = 𝛽2 + 𝜔zi0. The new-lesion progression is modelled by using logistic regression models
Logit{Pr(Di1 = 1|zi0)} = 𝛼1 + 𝛾1zi0,
Logit{Pr(Di2 = 1|Di1 = 0, zi0, zi1)} = 𝛼2 + 𝛾2zi1.
The probability of response for patient i at time 2 is written by
Pr(Si2 = 1|𝜃) = ∫ c2−∞ ∫
∞
−∞
Pr(Di1 = 0|zi0)Pr(Di2 = 0|D1 = 0, zi0, zi1)fY1Y2 (yi1yi2; 𝜃)dyi1dyi2,
where 𝜃 is the vector of parameters from the above models and c2 is the dichotomisation threshold (usually log(0.7),
representing at least a 30% shrinkage in the tumour size from baseline). The mean response probability is estimated by
Pr(S2 = 1|?̂?) = 1n ∑ni=1 Pr(Si2 = 1|?̂?), where ?̂? is themaximum likelihood estimator of 𝜃. A program is available in the paper
which uses R2Cuba to compute the above integration. An approximately (1-𝛼)% confidence interval for the probability of
response is constructed on the logit scale, that is, expit
{
l(?̂?) ± Φ−1(1 − 𝛼2 )
√
var(l(?̂?))
}
, where l(𝜃) = log Pr(S2=1|𝜃)1−Pr(S2=1|𝜃) and
var(l(?̂?)) is obtained by using the delta method.
2.4 Extended Augbin at a fixed time (t > 2)
We use the same assumptions and extend the Augbin to t follow-up times. The log tumour size ratios are modelled by
(Yi1, … ,Yit)′|z0 ∼ N((𝜇i1, … , 𝜇it)′,Σ). (1)
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An unstructured covariance matrix is used (although an alternative form may be needed if t is large enough).
The new-lesion progression is modelled by
Logit{Pr(Dit = 1|Di1 = … = Di(t−1) = 0, zi0, … , zi(t−1))} = 𝛼t + 𝛾tzi(t−1). (2)
We assume that the new-lesion progression depends only on the previous observed tumour size. The missing tumour
size because of new-lesion progression can be, therefore, treated as missing at random (MAR) as justified in Wason and
Seaman.7Pr(Yi(t+1) is missing |zi0, … , ziT) = Pr(Yi(t+1) is missing |zi0, … , zit). See the “sequential missingness at random”
section in Supporting Information for details. We also assume that dropout for other reasons before preplanned time is
MAR. The probability of response for patient i at time T can be written by
Pr(SiT = 1|𝜃) = ∫ cT−∞ ∫ c−∞ … ∫ c−∞ T∏
t=1
Pr(Dit = 0|Di1 = … = Di(t−1) = 0, zi0, … , zi(t−1))
× fY1,… ,YT (yi1, … , yiT ; 𝜃)dyi1...dyiT ,
(3)
where cT and c are the dichotomisation cut points (usually log(0.7) and log(1.2), representing at least a 30% shrinkage
in the tumour size from baseline and an increase in tumour size by more than 20%). Note that the response at a fixed
time T′ ⩽ T can be obtained by replacing T by T′ in the above formulas. The advantage is that the Equation 3 uses the
models to estimate probability of response of patients and missing data are MAR, it can be applied to patients who drop
out or progress before preplanned time. The probability is interpreted as the probability of patient i being a responder at
time T as if they were observed until T. A potential issue of Equation 3 is that the multivariate integration is computa-
tionally intensive. The mean response probability is estimated by averaging response probability over n patients given ?̂?.
An approximately (1 − 𝛼)% confidence interval is constructed as described in Section 2.3.
2.5 Modified Augbin at a fixed time
The objective for this section is to efficiently estimate the mean response probability using continuous tumour-size infor-
mation in a computationally efficient way. We assume that {no new-lesion progression occurs from time 1 to time T} and
{no tumour-growth progression} are conditionally independent given tumour size z̄t−1 = (z0, … , zt−1). We note this is a
strong assumption and assess the sensitivity to this assumption later on. The probability of response for patient i at a fixed
time t can be written by
Pr(response |z̄t−1) = Pr(no new-lesion progression until t|z̄t−1)
×Pr(no tumour progression at time t|z̄t−1).
Let 𝜋t be the probability of new-lesion progression at time t, t = 1, … ,T. Note that 𝜋t is a conditional probability given no
new-lesion progression occurring at previous time points. The log tumour size ratio Yi is allowed to depend on baseline
tumour size whereas new-lesion progression depends on the previous observed tumour size at the previous visit. We can
model Y by
(Yi1, … ,Yit)′|z0 ∼ fYi (·), l(𝜋it) = 𝜔t + 𝛽tzi(t−1). (4)
where fY(·) is a joint distribution and l(·) is the logit link function. We assume that 𝜋it(z̄t−1) = 𝜋it(zt−1). The probability of
response for patient i at a fixed time T can be written by
Pr(SiT = 1|z̄t−1, 𝜃) = T∏
t=1
{1 − 𝜋it(z̄t−1, 𝜃)}∫
cT
−∞ ∫
c
−∞
… ∫
c
−∞
fY1,… ,YT (yi1, … , yiT|zi0, 𝜃)dyi1...dyiT , (5)
where cT and c are the dichotomisation threshold and 𝜃 is a vector of parameters of themodels. We assume that fY(·) is the
probability density function of a multivariate normal distribution. The multivariate integration can then be calculated by
a highly efficient technique proposed by Genz and Bretz.9 The observed data for patient i is (Fi, zi). The l(𝜋i,F+1) can be
estimated by 𝜔F+1 + 𝛽F+1zi,F. Their probability of new-lesion progression at time t, t ⩾ Fi + 2 is estimated by
?̃?it =
1
nt − k
∑
j,yjt∈𝜑
𝜋jt, (6)
where nt is the number of patients with observed zt−1 and k is the number of patients who have log tumour size
ratio yt outside of the region of integration 𝜑 of Equation 5. We trim those k patients to avoid underestimating 𝜋it.
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This is similar to an idea of trimmed mean, which is used in many areas and has advantages under both normal and
nonnormal distributions.10,11
The vector 𝜃 consists of (T + 1) parameters that make up 𝜇, T(T + 1)∕2 parameters for 𝛴, and 2T parameters for the
logistic models. The mean response probability is estimated by Pr(ST = 1|?̂?) = 1n ∑ni=1 Pr(SiT = 1|?̂?), where ?̂? is the
maximum likelihood estimator of 𝜃. A (1 − 𝛼)% confidence interval for Pr(ST = 1|𝜃) can be constructed:[
Pr(ST = 1|?̂?) − Φ−1(1 − 𝛼∕2)√Var(Pr(ST = 1|?̂?)), Pr(ST = 1|?̂?) + Φ−1(1 − 𝛼∕2)√Var(Pr(ST = 1|?̂?)) ],
whereΦ is the standard normal distribution function. However, we found that themethod has better properties if we find
a confidence interval for logit{Pr(ST = 1|?̂?)} and transform back. Let l(𝜃) = log Pr(ST=1|𝜃)1−Pr(ST=1|𝜃) , we obtain Var(l(?̂?)) by using
the delta method, which is written by
var(l(?̂?)) ≈ (∇l(?̂?))Tvar(?̂?)∇l(?̂?),
where ∇l(?̂?) is the partial derivatives of l(𝜃). An approximately (1 − 𝛼)% confidence interval for the probability of
response is [
expit
{
l(?̂?) − Φ−1(1 − 𝛼∕2)
√
var(l(?̂?))
}
, expit
{
l(?̂?) + Φ−1(1 − 𝛼∕2)
√
var(l(?̂?))
}]
.
To summarise, the modified method uses a simplification for the relationship between new-lesion progressions and
tumour-growth progressions to use a more efficient procedure for multivariate integration.
2.6 Proposed method for BOR
We focus on the case where confirmation is not required but show briefly how the methodology can straightforwardly
allow for confirmation later. By the definition of BOR, a patient is a responder if they have at least 1 log tumour
size ratio smaller than log(0.7) before progression or maximum follow-up time. We define Ω1 = (log(0.7), log(1.2)),
Ω2 = (−∞, log(0.7)), and Ω3 = (−∞,∞) as the possible regions of integration corresponding to being classified as stable
disease, responder, and irrelevant variables. Let h be the time at which the patient is first classified as CR/PR. Hence, each
component of ȲT will fall into 1 of the 3 regions as
(Y1 … Yh−1 ∈ Ω1,Yh ∈ Ω2,Yh+1 … YT ∈ Ω3). (7)
The probability of response using BOR for patient i will be the sum over all possibilities of when the CR/PR is first
observed. Following the concept of the eAugbin, the probability of response can be written by
Pr(BORi = 1|𝜃) = T∑
h=1
∫
ΩT−h3
∫
Ω12
∫
Ωh−11
h∏
t=1
Pr(Dit = 0|Di1 = … = Di(t−1) = 0, zi0, … , zi(t−1))
× fY1,… ,YT (yi1, … , yiT ; 𝜃)dyi1...dyiT .
(8)
Similarly, following the concept of the mAug, the probability of response can be written by
Pr(BORi = 1|z̄t−1, 𝜃) = T∑
h=1
h∏
t=1
{1 − 𝜋it(z̄t−1, 𝜃)} ∫
ΩT−h3
∫
Ω12
∫
Ωh−11
fY1,… ,YT (yi1, … , yiT ; zi0, 𝜃)dyi1...dyiT . (9)
The mean response probability is then estimated by 1n
∑n
i=1 Pr(BORi = 1|?̂?), where ?̂? is the maximum likelihood esti-
mator of 𝜃. As before, we work on the logit scale, use the delta method to obtain the variance and then transform back to
construct the confidence interval for the mean response probability.
When confirmation is required, having 2 continued responses of CR/PR before progression, one can replace (7) with
(Y1 … Yh−1 ∈ Ω1,Yh,Yh+1 ∈ Ω2,Yh+2 … YT ∈ Ω3) with the sum in (9) going from 1 to T − 1.
2.7 Testing a difference in probability of response between 2 treatments
The abovemethods can be applied to single-arm trials. For a randomised trial where comparing the difference in response
probability is of interest, a minor addition is required.
We assume 2n patients are recruited with n patients randomised to each arm. Assumptions for log tumour size ratios
and new-lesion progression remain the same as in Section 2.4. We introduce an arm indicator R to the models, with 0 for
control and 1 for experimental arms. The log tumour size ratios are modelled by
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(Yi1,Yi2, … ,YiT)′|R, z0 ∼ N((𝜇i1, 𝜇i2, … , 𝜇iT)′,Σ),
where i indexes the ith patient, 𝜇i1 = 𝜇1 + 𝜂1R + 𝜔zi0, 𝜇i2 = 𝜇2 + 𝜂2R + 𝜔zi0. The new-lesion progression for T > t is
modelled by using logistic models
Logit{Pr(Dit = 1|Di1 = … = Dit−1 = 0, zi0, … , zi(t−1))} = 𝛼t + 𝛽tR + 𝛾tzi(t−1).
The probabilities of new-lesion progression for control and experimental arms are [1 + exp{−(𝛼t + 𝛾tzi(t−1))}]−1 and
[1 + exp{−(𝛼t + 𝛽t + 𝛾tzi(t−1))}]−1, respectively. Let 𝜃 be the vector of parameters with length (T2 + 9T2 + 2) from the above
models. The mean response probability at a fixed time is estimated by
Pr(S = 1|?̂?,R) = 12n 2n∑i=1 Pr(Si = 1|?̂?,R),
where ?̂? is the maximum likelihood estimator of 𝜃. We note that patients from both arms are included in the calculation
of the probability of response in an arm, as is recommended and justified in Wason and Seaman.7 The mean difference
in response probability at a fixed time is defined as the difference between mean response probabilities for the 2 arms.
It can be written by
mF(𝜃) = Pr(S = 1|R = 1, 𝜃) − Pr(S = 1|R = 0, 𝜃).
We obtain the variance of mF(?̂?) by using the delta method and use the Wald test to test whether mF(𝜃) is 0. Similarly,
we define the mean difference in response probability for BOR as
mB(𝜃) = Pr(BORi = 1|R = 1, 𝜃) − Pr(BORi = 1|R = 0, 𝜃).
Both the extended and modified methods can be used as in previous sections. Moreover, we provide a package mAugbin
in R including the extended augmented binary method as well as the modified augmented binary method. Changing of
integral regions to adapt RECIST or user defined criteria is allowed.
3 RESULTS
In this section, we evaluate the performance of the proposed methods in terms of precision and power using simula-
tions and a real data example. We use “Bin” to represent the method that just analyses the response outcomes as binary.
For single-arm trials, the binary method uses the R-package Hmisc to construct a Wilson interval for binary success
(S = 1 or BOR = 1). For 2-arm studies, the binary method is a logistic regression model that has parameters for treat-
ment group and baseline tumour size, from which the treatment effect can be tested. The terms “Augbin,” “eAugbin,”
and “mAug” refer to methods that use continuous information. They are, respectively, Wason and Seaman's method7
at 2 follow-up times, the extended method for more than 2 follow-up times, and the modified method for rapid computa-
tion. We use fixed time with varying numbers of follow-up times with cT and c being log(0.7) and −∞ and BOR without
confirmation as the endpoints.
3.1 Simulation study setup
Following the aforementioned notation, the observed data available for each patient is (Fi, zi). The observed data are
simulated as follows. First of all, baseline tumour size zi0 for patient i is generated from a uniform distribution and log
tumour size ratios of T follow-up time {yit ∶ t = 1, … ,T} are generated from amultivariate normal distribution. Tumour
size zit can then be calculated from zit = eyit zi0. Next, new-lesion progression indicators are generated from logistic models
with intercept 𝛼 and tumour size effect 𝛾 . A nonzero 𝛾 means that probability of new-lesion progression depends on the
tumour size at the previous time point. We define time to new-lesion progression as the first time when the new-lesion
progression occurs from the logistic models. Finally, tumour size observations of patient i after progression are replaced
as missing.
3.1.1 Single-arm trials assessing response at fixed time
Before generating 5000 replicates, we test the computation time for running one replicate using Augbin/eAugbin.
We generated one replicate of 75 patients. Baseline tumour size (Z0) is generated from a uniform distribution and log
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TABLE 1 Mean estimated probability of response and coverage of the modified augmented binary method (mAug) in comparison with
using dichotomised continuous method (Bin), augmented binary method (Augbin), and extended augmented binary method (eAugbin)
using fixed time with varying numbers of follow-up times
Mean of estimated probability Estimated coverage Reduction in width of 95% CI (%)
Scenario Augbin/ Augbin/ Augbin/
(𝛼, 𝛾) Time True Bin eAugbin mAug Bin eAugbin mAug eAugbin mAug
(−1.5, 0) 2 0.334 0.333 0.332 0.338 0.957 0.947 0.947 15.68 14.75
(−2.5, 0.2) 2 0.293 0.293 0.293 0.286 0.948 0.945 0.941 13.45 11.94
(−1.5, 0) 3 0.318 0.316 0.314 0.317 0.953 0.936 0.949 12.53 13.26
(−2.5, 0.2) 3 0.450 0.444 0.443 0.443 0.954 0.943 0.948 14.5 15.28
(−1.5, 0) 4 0.270 0.268 0.263 0.268 0.949 0.926 0.95 12.67 12.54
(−2.5, 0.2) 4 0.429 0.422 0.421 0.421 0.957 0.938 0.943 13.14 14.41
Abbreviation: CI, confidence interval.
tumour size ratios are generated from a multivariate normal distribution for 2 to 6 follow-up times. The (𝛼, 𝛾) are set to
(−1.5, 0) and (−2.5, 0.2). The value of 𝛼 = −1.5 corresponds to an 18% chance of developing new lesions between each visit.
The computation time for running 1 replicate using Augbin/eAugbin for 2 to 6 follow-up times are 0.04, 0.65, 2.28, 3.41,
and 4.47 minutes; while mAug at 6 follow-up times takes 0.09 minutes. We do not consider T > 4 because of the length of
time need to simulate 5000 replicates for eAugbin. The simulation settings of log tumour size ratios for 2 follow-up times
is a similar formulation to Wason and Seaman,7 that is,
Z0 ∼ U(0, 1),Y2 ∼ N
[
log(0.7)
(
.5
1
)
,
(
.5 .5
.5 1
) ]
.
The settings for T = 3 and4 are Z0 ∼ U(0, 1),
Y3 ∼ N
[
log(0.7)
(
.5
.75
1
)
,
(
.5 .5 .5
.5 .75 .75
.5 .75 1
)]
,Y4 ∼ N
⎡⎢⎢⎢⎣ log(0.7)
⎛⎜⎜⎜⎝
.25
.5
.75
1
⎞⎟⎟⎟⎠ ,
⎛⎜⎜⎜⎝
.25 .25 .25 .25
.25 .5 .5 .5
.25 .5 .75 .75
.25 .5 .75 1
⎞⎟⎟⎟⎠
⎤⎥⎥⎥⎦ .
Table 1 shows mean estimated response probability and coverage for Bin, Augbin/eAugbin, and mAug for 2, 3, and 4
follow-up times for 5000 replicates. The columns 10 to 11 show the reduction in 95% confidence interval (CI). They are,
respectively, the average of [1− (CI width of Augbin)/(CI width of Bin)] and [1− CI width of mAug)/(CI width of Bin)].
As seen, in all cases, eAugbin and mAug have narrower CIs compared with Bin. For example, mAug reducing the CI
width by 14% means that Bin needs an additional 35% sample size to obtain a similar width. The mAug has a similar
coverage to Augbin at t = 2. For larger t, it appears the mAug method has a better coverage probability (ie, closer to the
nominal value) than eAugbin. The reduction in confidence interval width, compared to the binary method, appears to be
similar for the 2 methods. Thus for single-arm trials it appears mAug shows a significant improvement in computational
efficiency without notably poorer statistical characteristics compared to eAugbin.
3.1.2 Randomised trials using response at fixed time
We consider a two-arm trial with a control and experimental arm for 2 follow-up times. Each arm has 75 patients that
have been allocated at random. Baseline (Z0) is generated from a U(0, 1) distribution. The mean log tumour size ratios
between each visit are generated from a normal distribution with mean 𝜇 and variance 12 . We set 𝜇 = log(0.7) + 𝛿𝜏 + 𝜓 ,
where 𝛿 = 1 for control and 𝛿 = −1 for experimental arms, 2𝜏 is the difference in the mean log tumour size ratio and 𝜓
reflects the effectiveness of the control treatment. This is a similar formulation as.7
Figure 1 compares the powers for Bin, eAugbin, andmAugmethods for randomised trials. The figure on the right shows
the power over treatment effect when 𝜏 =.35. As seen, there is a clear power gain when using either mAug or Augbin.
mAug performs very closely to Augbin. The empirical Type I error when the difference is 0 for Augbin and mAug are
0.054 and 0.055, respectively.
3.1.3 Noncomparative trials for BOR
Using the binary composite outcome, patients are classified as responders if they have a CR/PR before time F.
The computation time for running 1 replicate usingAugbin/eAugbin and BOR for 3 to 6 follow-up times are 0.05, 0.09, 0.3,
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FIGURE 1 Power of the 3 methods for fixed time as the mean log tumour size ratio (𝜏) varies and as 𝜓 varies at 𝜏 = .35
TABLE 2 Mean estimated probability of response and coverage using best observed response without confirmation with Bin, eAugbin, and
mAug for maximum number of visits from 4 to 7
Mean of estimated probability Estimated coverage Reduction in width of 95% CI(%)
(𝛼, 𝛾) n Time True Bin eAugbin mAug Bin eAugbin mAug eAugbin mAug
(−1.5, 0) 75 4 0.4 0.4 0.404 0.403 0.959 0.954 0.955 16.5 15.9
(−1.5, 0) 75 5 0.391 0.393 0.398 0.396 0.943 0.951 0.952 16.6 15.9
(−1.5, 0) 75 6 0.386 0.39 0.395 0.394 0.959 0.954 0.955 16.7 16
(−1.5, 0) 150 7 0.382 0.382 — 0.387 0.944 — 0.957 — 16.6
(−2.5, 0.2) 75 4 0.46 0.457 0.462 0.461 0.941 0.957 0.957 16.8 17.3
(−2.5, 0.2) 75 5 0.452 0.448 0.454 0.452 0.954 0.96 0.96 18.2 17.2
(−2.5, 0.2) 75 6 0.446 0.442 0.449 0.447 0.942 0.962 0.961 18.3 17.2
(−2.5, 0.2) 150 7 0.441 0.441 — 0.446 0.95 — 0.96 — 18.3
and 0.56 minutes; while mAug at 6 follow-up times takes 0.22 minutes. Again, we use 5000 replicates of 75 patients.
Baseline tumour size is generated from a uniform distribution (0, 1). The log tumour size ratios are generated from mul-
tivariate normal distribution for 4, 5, 6, and 7 follow-up times with 𝜎2tt = 1, t = 4, 5, 6, 7. Regardless of the number of visits
after baseline, we set the mean log tumour size ratios at the end of the treatment to log(0.7). For example, the case where
T = 4 refers to having 4 visits after baseline and 𝝁 being set to 0.25 log (0.7), 0.5 log (0.7), 0.75 log (0.7), log (0.7). For
computational reasons, eAugbin was included for up to T = 6. Table 2 shows the operating characteristics of eAugbin,
mAug, and Bin for maximum number of visits varying from 4 to 7. Overall, mAug reduces the average width of the CI by
at least 16% compared with Bin. This is equivalent to needing a sample size of around 101 (1.162 × 75), to obtain a sim-
ilar average width using Bin. The reduction in width is slightly higher when there is a tumour size effect on new-lesion
progression.
3.1.4 Comparative trials for BOR
To illustrate results of the mAug method for a two-arm trial, we consider the case where each arm has 75 patients
and patients are followed for 4 time points. The mean log tumour size ratios for each time point is (log(0.7) + .25𝛿𝜏),
(log(0.7)+.5𝛿𝜏), (log(0.7)+.75𝛿𝜏) and (log(0.7)+𝛿𝜏), where 𝛿 = 1 for control and 𝛿 = −1 for experimental arms respectively.
We also consider the method of Karrison et al.6. They proposed to assign the highest observed log tumour ratio
(referred to as worst outcome henceforth) for deaths and dropouts, and best possible outcome for complete responders,
but do not explicitly say how to deal with BOR. We use worst outcome only if the first non-baseline observation was a
progression and otherwise use the lowest logtumour before progression. Figure 2 compares the powers for Bin, mAug,
and Karrison's methods in comparative trials for 4 time points when BOR is used. The empirical type I error when the
difference is 0 for Binary, mAug, and Karrison are 0.041, 0.058, and 0.042, respectively. Although there is a slight inflation
in type I error rate for mAug, in general, there is a consistent power advantage when using mAug compared to using Bin
and the power of mAug is very similar to Karrison's method.
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FIGURE 2 Power of the binary, mAug, and Karrison's methods for best observed response for 4 time points as the mean log tumour size
ratio (𝜏) varies
3.2 Case study: HORIZON II
The HORIZON II (clinicaltrials.gov identifier: NCT00384176) is a 3-arm colon cancer trial sponsored by AstraZeneca.
Patients initially were randomly assigned 1:1:1 to placebo, cediranib 20 mg once daily, and cediranib 30 mg once daily.
Later, subsequent patients were randomly assigned 1:2 to placebo or cediranib 20 mg.12 The numbers of patients with
baseline record for the 3 arms are 346, 484, and 209. The tumour sizes of patients were measured every 6 weeks up
to 24 weeks and then every 12 weeks. Figure S1 in Supporting Information shows a waterfall plot for the individual
reduction in tumour size at week 24 from the baseline. There are cases that participants are classified as responders before
progression which results in different response estimates between fixed time and BOR.
We used a permutation test to calculate the empirical type I error rate. Data from baseline, 6, 12, 18, and 24 weeks,
were used. We simulated 5000 replicates, with the treatment assignment label shuffled randomly in each replicate.
For each replicate, we tested the difference in probability of BOR between 2 treatment arms using mAug with 4 follow-up
times. The empirical type I error for no difference between placebo and cediranib 20 mg is 0.0558 and that between
placebo and cediranib 30 mg is 0.0518. These are within Monte Carlo standard error of a true type I error of 0.05
(MC error +∕− 0.006).
Figure S2 in Supporting Information shows themean estimated response probability using the 3methods and fixed time
with between 2 and 5 follow-up times for Placebo, 20 and 30 mg, respectively. The mean estimated response probability
decreases as the number of time points increases. Generally, the estimated mean probabilities of response for 3 methods
are similar. Figure S3 in Supporting Information shows a residual plot of the fitted multivariate normal model for the
20mg arm using 3 follow-up times. The residuals look close to normally distributed, though there is a pattern the variance
of the residuals may be decreasing as the fitted values increase. In general, it may be beneficial to apply a transformation
such as the Box-Cox family.
Table 3 reports the width of the 95% CI for each arms probability of response using fixed time. The width corresponds
to the length of the vertical lines shown in Figure S2. The 95% CI widths of eAugbin andmAug are considerably narrower
than that of Bin. We compared Placebo and cediranib 20 mg as well as Placebo and cediranib 30 mg using mAug BOR
and Bin BOR for 4 to 6 time points. Results show that the mAug method gives a considerably smaller 95% CI than the
TABLE 3 The width of 95% CI for 3 methods using fixed time with between 2 and 5 follow-up times for individual arm
Time
Placebo Cediranib 20 mg Cediranib 30 mg
Method 2 3 4 5 2 3 4 5 2 3 4 5
Bin 0.113 0.114 0.111 0.105 0.111 0.112 0.111 0.111 0.134 0.133 0.13 0.124
eAugbin 0.073 0.074 0.073 0.07 0.072 0.075 0.074 0.064 0.088 0.088 0.088 0.085
mAug 0.086 0.087 0.087 0.08 0.086 0.088 0.086 0.088 0.105 0.105 0.104 0.096
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Bin method. The maximum width of the 95% CI for mAug is 0.131 for comparing Placebo with 30 mg, while the width is
0.174 for Bin (See Table S1 in Supporting Information).
4 DISCUSSION
In this paper, we have considered how the augmented binary method of Wason and Seaman7 can be extended to be
applicable for a wider range of phase II oncology trials. We have made 3 contributions. The first is to extend the existing
method to more than 2 follow-up times. The second is a modified method that considerably reduces the computational
time by making a simplifying assumption about the relationship between new lesions and tumour size change. The third
is amechanism for using both of thesemethods when the endpoint is based around the best observed RECIST observation
before progression, which is a common phase II oncology endpoint.
We have shown that all proposed methods carry the same good properties as the augmented binary method.
They provide extra precision, ie, they require a smaller sample size for the same precision (compared to the traditional
analysis of analysing response as a binary outcome) in single-arm trials and are more powerful in comparative trials. We
includeKarrison'smethod,which directly tests the continuous tumour change outcome.As found inWason and Seaman,7
in the comparison of using fixed time, Karrison's method performed better than Augbin when the probabilities of new
lesions were different between arms andworse when themean tumour size changes were different, whichwe expect to be
true for BOR as well. We show results comparing the proposed Augbin on BOR andKarrison's methodwhen the probabil-
ities of new lesions are different between arms.We note in this case the Augbin and Karrison's method give similar power.
Karrison's method is simpler to implement, but the Augbin estimates a quantity that is more clinically interpretable.
The difference between the modified (mAug) and extended (eAugbin) methods is that the former uses the estimated
probability of new-lesion progression whereas the latter more correctly incorporates variation by averaging all possibili-
ties. Estimation of probabilities using themodified methodmight be biased if only a few patients remain in a trial at some
time point. The mAug has similar properties to eAugbin with respect to precision and power when using BOR.
The extended and modified methods define progression as 20% increase from baseline, whereas RECIST defines pro-
gression as 20% increase from the minimum point observed. On the HORIZON II dataset, we examined the number of
patients who had their BOR being PR or CR by both of these definitions. The number is the same for both approaches for
all number of follow-up times. This indicates that considering progression as being 20% from baseline does not substan-
tially affect the estimation. However, we should point out that the eAugbin would be able to use the RECIST definition of
progression by including a suitable indicator variable in the integrand as well as mAug by changing regions of integration
of variables. Details about how to use the true definition can be found in Supporting Information.
All proposed augmented binary methods involve modelling the log tumour size ratio and new-lesion progression indi-
cators. The new lesion indicator can include other reasons for progression such as unequivocal progression of nontarget
lesions. It may also be possible to include a second logistic regression model for the nontarget lesions separately to
increase efficiency further. The log tumour size ratio has been shown to be approximately normally distributed in past
data in oncology.13 Wason and Seaman7 show results from the Augbin can be quite sensitive to deviations from the nor-
mal assumption. We find that the residuals of the log tumour ratio in our real data application are close to being normal.
However, in general, it may be useful to use a transformation to ensure the normality assumption is as close to true as
possible. One could also use other models rather than multivariate normal. An alternative approach is joint latent mod-
elling of longitudinal tumour size data and the new-lesion progression. One can use a random effect model for the repeat
tumour size measure and a latent class membership for new-lesion progression. By membership, we mean a participant
has probabilities of belonging to latent classes. Each class refers to the time when new-lesion progression occurs. More-
over, tumour-growth progression or new lesions appearing at a time period results in the patient's tumour size measure
being missing for all subsequent time periods. Considering this monotone missing pattern in log tumour size, the joint
probability of log tumour size can be written as the product of a set of conditional probabilities of current log tumour size
ratio given previous data.14 Complete responses do cause an issue with the proposed methodology as they mean the log
tumour ratio is negative infinity—in practice, we would set complete response to an extreme value of log tumour size
ratio. Potentially an alternative model such the censored normal distribution15 could be used. Future work is warranted
to investigate whether this more complicated methodology is worth applying.
We have only considered ORR in this work. However, the proposed method can be adjusted for using disease con-
trol rate where SD is included. The probability of patients being classified as SD can be calculated by adapting the inner
integral in equations from log(0.7) to log(1.2). The joint distribution of the probability of being in each ordered category
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(CR/PR, SD, and PD) could be estimated by suitably extending the delta-method approach. An increasingly commonly
used phase II endpoint is progression-free survival (PFS). Response-based endpoints focus on success, and PFS is inter-
ested in progression. Further development of the Augbin from response to progression so that it can be applied to improve
analyses of PFS is an area of current work.
5 SOFTWARE
For estimating the probability of response for fixed time and for BOR, a packagemAugbin in R is available at https://sites.
google.com/site/jmswason/supplementary-material for the methods proposed in this paper. The package includes both
the eAugbin and mAug.
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